Availity, the nation’s leading real-time health information network, and Concert, the leading provider of clinical content and payment accuracy solutions for advanced diagnostics, have partnered to digitize and automate the prior authorization and payment processes for genetic tests. Together the companies will enable more consistent, transparent, and instantaneous prior authorizations, reducing administrative burden in the delivery of precision medicine.
With advancements in genetic diagnostics and therapies, providers are better able to personalize patient care. However, genetic testing is an evolving and complex space that is expensive to administer. These tests represent a disproportionately high number of prior authorization clinical reviews, and Utilization Management (UM) teams struggle to keep current with new tests, rapidly evolving clinical guidelines, and complex state-level biomarker regulations. These challenges extend to the health plan’s coding and billing functions. Frequently ordered prenatal, oncology, and pharmacogenetic tests are commonly billed with between two and 10 codes.1 The complexity of these claims means they are more likely to be denied or held for manual review, leading to delay, waste, confusion, and frustration for plans, providers, and patients.
Also Read: US Radiology Appoints Caitlin Zulla as CEO
In an effort to solve these challenges, the companies will integrate Concert’s clinical criteria, coding standards, and Concert GTU® test identifier with Availity’s End-to-End Authorization solution. Doing so will transform manual and error-prone administrative processes into automated authorization recommendations within existing health plan and provider workflows. The goal of this collaboration is that:
- Providers experience greater consistency and transparency in authorizations, many of which are rendered instantly,
- Health plans benefit from a streamlined prior authorization process, definitive knowledge of the service rendered, and reduced medical director burden surrounding complex authorization and claim reviews, and
- Patients benefit from less delay and uncertainty when their provider is ordering a genetic test, and fewer surprise bills after the fact.
“At Concert, we envision a day when laboratory test reimbursement is determined instantly at the point of patient care. To make this possible, Concert built a flexible data platform for policy and coding that integrates wherever work happens,” said Rob Metcalf, CEO of Concert. “Availity’s information network facilitates healthcare operations across the nation. Concert is delighted to power that network and together enable efficient, evidence-based precision health.”
“At Availity, our goal is to accelerate access to the right care by completely automating critical processes like prior authorization and payment accuracy. Our partnership with Concert represents a critical step forward in this mission by addressing clinically complex conditions, which are among the most time-consuming authorization requests,” said Matt Cunningham, Availity Executive Vice President of Product. “Availity seamlessly integrates Concert’s clinical content within UM workflows and across the care continuum, so health plans and providers have the insights needed to determine and deliver appropriate care, while reducing the wait times that prevent patients from receiving timely access to that care.”
SOURCE: Businesswire